Characterization of myeloid malignancies with TP53 mutations and comparison to P53 expression by immunohistochemical staining methods

Int J Lab Hematol. 2020 Apr;42(2):e35-e37. doi: 10.1111/ijlh.13088. Epub 2019 Aug 7.

Authors

Kristin H Karner^{1

2}, Jessica L Kohan², Sheryl R Tripp², Mohamed E Salama³

Affiliations

¹ Department of Pathology, University of Utah, Salt Lake City, Utah.
² ARUP Laboratories, Salt Lake City, Utah.
³ Department of Pathology, Mayo Clinic, Rochester, Minnesota.

PMID: 31390152
DOI: 10.1111/ijlh.13088

No abstract available

Publication types

Comparative Study
Letter

MeSH terms

Acute Disease
Adult
Aged
Aged, 80 and over
Female
Humans
Immunohistochemistry / methods
Leukemia, Myeloid / diagnosis
Leukemia, Myeloid / genetics*
Leukemia, Myeloid / metabolism
Male
Middle Aged
Mutation*
Myeloproliferative Disorders / diagnosis
Myeloproliferative Disorders / genetics*
Myeloproliferative Disorders / metabolism
Staining and Labeling / methods
Tumor Suppressor Protein p53 / biosynthesis
Tumor Suppressor Protein p53 / genetics*
Young Adult

Substances

Tumor Suppressor Protein p53